Autopsy report · NCT01994213

A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor

“The applicant decided to close the study”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 years 1 month after it had already started.
• Ran for about 4 years 7 months before it stopped.
• 53 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Jiangsu HengRui Medicine Co., Ltd.

Sponsor type

Industry

Conditions

Gastroenteropancreatic Neuroendocrine Tumor

Interventions

Famitinib

Participants

53

Sites

1

Countries

China

Trials that died the same way

• Off-the-Shelf Splints Versus Occupational Therapy Splints for Treatment of Trapeziometacarpal Arthrosis
  “Due to the principal investigator leaving the institution and slow enrollment, we have decided to close the study prior to study completion” (80% match in meaning)
• Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant
  “Study sponsor decided to close study.” (79% match in meaning)
• L-Menthol Injection as a Novel Technique During Colonoscopy
  “Sponsor/Investigator has decided to close out the study” (76% match in meaning)
• Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells
  “Due to slow accrual, the investigator decided to close the study.” (76% match in meaning)
• A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary
  “Sponsor Decision to close study” (75% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.